Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

Author： Naoi M.   Maruyama W.   Youdim M. B. H.   Yu P.   Boulton A. A.  

Publisher： VSP

ISSN： 1568-5608

Source： Inflammopharmacology, Vol.11, Iss.2, 2003-06, pp. : 175-181

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoamine oxidase A and B inhibitors

By Jegham S.   George P.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1143-1150

Informa Healthcare

Access to resources Recommend Favorite

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors in Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Selective and potent monoamine oxidase type B inhibitors: substituted semicarbazones and acylhydrazones of aromatic aldehydes and ketones

By Bernard S.   Paillat C.   Oddos T.   Seman M.   Milcent R.  

European Journal of Medicinal Chemistry, Vol. 30, Iss. 6, 1995-01 ,pp. : 471-482

Elsevier

Access to resources Recommend Favorite

Community and Long-Term Care Management of Parkinson's Disease in the Elderly: Focus on Monoamine Oxidase Type B Inhibitors

By Chen Jack J.  

Drugs & Aging, Vol. 24, Iss. 8, 2007-01 ,pp. : 663-680

Adis International

Access to resources Recommend Favorite